The Toxicology of Perfluorooctanoate
Top Cited Papers
- 1 January 2004
- journal article
- review article
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 34 (4) , 351-384
- https://doi.org/10.1080/10408440490464705
Abstract
PFOA is a peroxisome proliferator (PPAR agonist) and exerts morphological and biochemical effects characteristic of PPAR agonists. These effects include increased β-oxidation of fatty acids, increases in several cytochrome P-450 (CYP450)-mediated reactions, and inhibition of the secretion of very low-density lipoproteins and cholesterol from the liver. These effects on lipid metabolism and transport result in a reduction of cholesterol and triglycerides in serum and an accumulation of lipids in the liver. The triad of tumors observed (liver, Leydig cell, and pancreatic acinar-cell) is typical of many PPAR agonists and is believed to involve nongenotoxic mechanisms. The hepatocellular tumors observed in rats are likely to have been the result of the activation of the peroxisome proliferator activated receptor α (PPARα). The tumors observed in the testis (Leydig-cell) have been hypothesized to be associated with an increased level of serum estradiol in concert with testicular growth factors. The mechanism responsible for the acinarcell tumors of the pancreas in rats remains the subject of active investigation. The mechanism resulting in the hepatocellular tumors in rats (PPARα activation) is not likely to be relevant to humans. Similarly, the proposed mechanism for Leydig-cell tumor formation is of questionable relevance to humans. Acinar tumors of the pancreas are rare in humans, and the relevance of the these tumors, as found in rats, to humans is uncertain. Epidemiological investigations and medical surveillance of occupationally exposed workers have not found consistent associations between PFOA exposure and adverse health effects.Keywords
This publication has 116 references indexed in Scilit:
- HMG CoA Reductase Inhibitor-Induced Myotoxicity: Pravastatin and Lovastatin Inhibit the Geranylgeranylation of Low-Molecular-Weight Proteins in Neonatal Rat Muscle Cell CultureToxicology and Applied Pharmacology, 1997
- Peroxisome Proliferators: Species Differences in Response of Primary Hepatocyte CulturesAnnals of the New York Academy of Sciences, 1996
- PPAR: a mediator of peroxisome proliferator actionMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1995
- Effects of prolonged administration of perfluorooctanoic acid on hepatic activities of enzymes which detoxify peroxide and xenobiotic in the ratToxicology, 1994
- Lack of Peroxisome Proliferation in Marmoset Liver Following Treatment with Ciprofibrate for 3 YearsFundamental and Applied Toxicology, 1994
- On the interactions of perfluorochemical emulsions with liver microsomal membranesJournal of Fluorine Chemistry, 1993
- The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acidBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- Covalent binding of perfluorinated fatty acids to proteins in the plasma, liver and testes of ratsChemico-Biological Interactions, 1992
- On the mechanism of the hepatocarcinogenicity of peroxisome proliferatorsChemico-Biological Interactions, 1991
- Disposition of perfluorooctanoic acid in the rat after single and subchronic administrationBulletin of Environmental Contamination and Toxicology, 1990